Breast Cancer
Conditions
Brief summary
This study aims to describe in detail the patient journey from diagnosis to the beginning of treatment and patterns of care of hormone receptor- positive, HER2-negative de novo or recurrent metastatic breast cancer between January 2018 and December 2020 in Brazil.
Interventions
None listed
Sponsors
Brazilian Breast Cancer Study Group (GBECAM)
Latin American Cooperative Oncology Group
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women ≥18 years old * Histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer * Hormone receptor-positive defined as 1% to 100% of tumor nuclei positive for Estrogen - - Receptor and/or Progesterone Receptor, as per ASCO/CAP Guideline 2020 - or Allred score of ≥3 * HER2-negative defined as IHC result is 0/1+ or 2+ with ISH negative as per ASCO/CAP Guideline 2018 * Diagnosed with de novo or recurrent metastatic breast cancer between January 2018 -and December 2020 * Public health system or private health system
Exclusion criteria
* Male Breast Cancer * First-line treatment for mBC received through clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of type of first-line treatment | from January 2018 to December 2020 |
Secondary
| Measure | Time frame |
|---|---|
| BC pathological characterization | from January 2018 to December 2020 |
| Rate of diagnostic tests to define breast cancer molecular subtypes performed | from January 2018 to December 2020 |
| The PFS, defined as time from treatment start until progression (by image or physical exam) or death | from January 2018 to December 2020 |
| First-line treatment according to the drug name by type of health care coverage (public vs private) | from January 2018 to December 2020 |
| Patients' demographics characteristics | from January 2018 to December 2020 |
| Timeline from first symptom to diagnosis | from January 2018 to December 2020 |
| Timeline from diagnosis to molecular test | from January 2018 to December 2020 |
| Timeline from diagnosis to the beginning of treatment | from January 2018 to December 2020 |
| Patients' socioeconomic characteristics | from January 2018 to December 2020 |
| The PFS will be evaluated by type of health care coverage (public vs private). | from January 2018 to December 2020 |
Countries
Brazil
Outcome results
None listed